Tonix Pharmaceuticals Surges to 400th in Trading Volume with $23.6 Million in Shares Exchanged

On March 24, 2025, Tonix Pharmaceuticals Holding Corp. (TNXP) saw a significant surge in trading volume, with a total of $23.6 million in shares exchanged, marking a 209.32% increase from the previous day. This surge placed Tonix at the 400th position in terms of trading volume for the day. The stock price of Tonix rose by 32.48%, marking the third consecutive day of gains, with a cumulative increase of 85.25% over the past three days.

Tonix Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, licensing, acquisition, and development of therapeutics. The company's recent stock performance can be attributed to several key developments. Notably, Tonix's stock experienced a significant jump following the announcement that the FDA would not require an Advisory Committee meeting for one of its experimental pox vaccines. This news was well-received by investors, contributing to the stock's upward trajectory.

Additionally, Tonix reported promising results for TNX-1500, a humanized monoclonal antibody designed to prevent organ transplant rejections. This development has further bolstered investor confidence in the company's pipeline and its potential for future growth. The upcoming earnings report, scheduled for May 12, 2025, is also anticipated to provide further insights into the company's financial performance and strategic direction.